Kite Pharma | MediPaper Medical Communications Ltd.

Posts

CAR-T axicabtagene ciloleucel granted Orphan Drug designation for B-Cell Lymphoma by the Japan MHLW

5th October 2018/0 Comments/in Haematology, ImmunoOncology, Immunotherapy, Medical News Asia, Oncology /by News Feed

TOKYO and BASKING RIDGE, N.J., October 3, 2018 /PRNewswire/ — The Japan Ministry of Health, Labour and Welfare (MHLW) granted the Orphan Drug designation to axicabtagene ciloleucel (KTE-C19, Daiichi Sankyo) for the treatment of diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBL), and transformed follicular lymphoma (TFL), which are all aggressive forms of non-Hodgkin lymphoma (NHL).

Ribociclib FDA label updated to include pre- and perimenopausal women

©United States Food and Drug Agency

CAR-T Axicabtagene ciloleucel FDA approved for relapsed or refractory large B-cell lymphoma

18th October 2017/0 Comments/in US FDA Onc\Haem Approvals /by News Feed

On 18 October 2017, the FDA granted regular approval to CAR-T axicabtagene ciloleucel (Yescarta®, Kite Pharma) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of prior systemic therapy. Large B-cell lymphoma includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.